A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists-Reference-Cited by-同舟云学术

A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists

Published:2016-05-11 Issue:8 Volume:23 Page:1255-1261
ISSN:1351-5101
Container-title:European Journal of Neurology
language:en
Short-container-title:Eur J Neurol

Author:

Rizos A.¹,Sauerbier A.¹²,Antonini A.³,Weintraub D.⁴,Martinez-Martin P.⁵,Kessel B.⁶,Henriksen T.⁷,Falup-Pecurariu C.⁸,Silverdale M.⁹,Durner G.¹,Røkenes Karlsen K.¹,Grilo M.¹,Odin P.¹⁰¹¹,Chaudhuri K. Ray¹²¹²,

Affiliation:

1. King's College Hospital; London UK

2. King's College London; London UK

3. Parkinson and Movement Disorders Unit; IRCCS Hospital San Camillo; Venice and University of Padua; Padua Italy

4. Perelman School of Medicine at the University of Pennsylvania; Philadelphia PA USA

5. National Center of Epidemiology and CIBERNED; Carlos III Institute of Health; Madrid Spain

6. King's College Hospital; Princess Royal University Hospital site; Orpington UK

7. University Hospital of Bispebjerg; Copenhagen Denmark

8. County Emergency Clinic Hospital; Faculty of Medicine; Transilvania University Brasov; Brasov Romania

9. Greater Manchester Neuroscience Centre; Manchester UK

10. University of Lund; Lund Sweden

11. University Hospital Reinkenheide; Bremerhaven Germany

12. University Hospital Lewisham; London UK

Funder

National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre

South London and Maudsley NHS Foundation Trust

King’s College London

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ene.13034/fullpdf

Reference19 articles.

1. A reassessment of risks and benefits of dopamine agonists in Parkinson's disease;Antonini;Lancet Neurol,2009

2. Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and prevention;Antonini;Drug Saf,2009

3. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table;Grosset;Mov Disord,2004

4. Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery?;Chaudhuri;J Neural Transm,2013

5. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients;Weintraub;Arch Neurol,2010

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dopamine agonists in the treatment of Parkinson's disease: the show must go on;Journal of Neural Transmission;2024-09-11

2. Impulse control disorder: Review on clinical, pharmacologic, and genetic risk factors;Revue Neurologique;2024-09

3. Diagnostics and treatment of impulse control disorders, psychosis and delirium: systemic review-based recommendations - guideline “Parkinson’s disease” of the German Society of Neurology;Journal of Neurology;2024-07-24

4. Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus;Movement Disorders;2024-01-17

5. Validation of the Italian version of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease-Rating Scale (QUIP-RS) in an Italian Parkinson’s disease cohort;Neurological Sciences;2024-01-17